Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sipavibart - AstraZeneca

Next Previous
Drug Profile

Sipavibart - AstraZeneca

Alternative Names: AZD-3152; Kavigale

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RQ Bio
  • Developer AstraZeneca; RQ Bio
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Coronavirus spike glycoprotein inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 12 Jun 2025 Nova Southeastern University plans a phase II trial for Post acute COVID-19 syndrome in USA (IM) in June 2025 (NCT07021794)
  • 11 Feb 2025 AstraZeneca completes a phase-III (SUPERNOVA) trial for COVID-2019 infections (Prevention, In adolescents, In adults, In children, In the elderly) in Argentina, Denmark, France, South Africa, Taiwan, Turkey and United Kingdom (IM) (NCT05648110)
  • 20 Jan 2025 Registered for COVID-2019 infections (In adolescents, In the elderly, Prevention, In adults) in Iceland, Liechtenstein, Norway, European Union (IV) - Frist global approval

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top